Phoenix Holdings Ltd. lessened its position in shares of Evogene Ltd. (NASDAQ:EVGN) by 80.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 50,414 shares of the biotechnology company’s stock after selling 212,719 shares during the quarter. Phoenix Holdings Ltd. owned 0.20% of Evogene worth $188,000 at the end of the most recent reporting period.
Separately, Harel Insurance Investments & Financial Services Ltd. purchased a new stake in Evogene in the third quarter worth about $139,000. 24.06% of the stock is currently owned by hedge funds and other institutional investors.
Shares of EVGN opened at $2.83 on Friday. The business has a 50-day simple moving average of $3.22 and a two-hundred day simple moving average of $1.94. The stock has a market cap of $72.87 million, a price-to-earnings ratio of -3.54 and a beta of 1.17. Evogene Ltd. has a 52 week low of $0.75 and a 52 week high of $5.30.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements.
Further Reading: Black Swan
Want to see what other hedge funds are holding EVGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evogene Ltd. (NASDAQ:EVGN).
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.